Zinc and the common cold

Zinc supplements (frequently zinc acetate or zinc gluconate lozenges) are a group of dietary supplements that are commonly used in an attempt to treat the common cold.[1] There is no evidence that zinc supplementation prevents colds in the general population. There is evidence that properly composed zinc lozenges can shorten the duration of colds, but this effect has not been reported for ordinary oral zinc tablets. Adverse effects with zinc supplements by mouth include bad taste and nausea.[1]

The intranasal use of zinc-containing nasal sprays has been associated with the loss of the sense of smell; consequently, in June 2009, the United States Food and Drug Administration (USFDA) warned consumers to stop using intranasal zinc.[1]

The human rhinovirus – the most common viral pathogen in humans – is the predominant cause of the common cold.[2] The hypothesized mechanism of action by which zinc reduces the severity and/or duration of cold symptoms is the suppression of nasal inflammation and the direct inhibition of rhinoviral receptor binding and rhinoviral replication in the nasal mucosa.[1]

Effectiveness

A statistical analysis which pooled seven randomized trials with 575 participants with naturally acquired colds concluded that there was no evidence that zinc acetate and zinc gluconate lozenges differed in their efficacy, there being on average 33% shorter colds in the zinc lozenge groups.[3] In addition, the analysis found that there was no evidence that zinc doses over 100 mg/day led to greater efficacy in the treatment of the common cold.

Based on individual patient data of 199 common cold patients, zinc acetate lozenges indicated that such lozenges may shorten common cold duration by 36% (2.7 days),[4] and increased the recovery rate by rate ratio 3.1.[5]

Two statistical analyses highlighted that the effect of zinc lozenges varied depending on the initial length of the cold, with longer colds experiencing substantially greater reduction in duration that short colds.[6]

A 2021 systematic review and meta-analysis on respiratory tract infections found that zinc modestly reduced symptom severity by day 3 and shortened illness duration by about two days, though the evidence was of low to very low certainty. Zinc offered minimal benefit in preventing infections and was associated with an increased risk of mild side effects, such as nausea and irritation.[7]

A 2024 Cochrane Review found little to no evidence that zinc prevents the common cold or reduces symptom severity, though it may modestly shorten the duration of symptoms. Zinc lozenges were associated with a reduction in cold duration, but the evidence was of low certainty and varied across studies.[8]

Safety

High doses of zinc have been given to patients with various diseases for several months without concerns, and zinc is a standard treatment for Wilson's disease, which usually means taking high doses long-term.

There have been several cases of people using zinc nasal sprays and suffering a loss of sense of smell.[1] In 2009 the US Food and Drug Administration issued a warning that people should not use nasal sprays containing zinc.[1]

Mechanism of action

The hypothesized mechanism of action by which zinc reduces the severity and/or duration of cold symptoms is the suppression of nasal inflammation and the direct inhibition of rhinoviral receptor binding and rhinoviral replication in the nasal mucosa.[1]

References

  1. ^ a b c d e f g "Zinc – Fact Sheet for Health Professionals". Office of Dietary Supplements, US National Institutes of Health. February 11, 2016. Retrieved January 7, 2018.
  2. ^ "Common Cold and Runny Nose". United States Centers for Disease Control and Prevention. September 26, 2017. Retrieved January 7, 2018.
  3. ^ Hemilä, H (2017). "Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage". JRSM Open. 8 (5) 2054270417694291. doi:10.1177/2054270417694291. PMC 5418896. PMID 28515951.
  4. ^ Hemilä, H; Petrus, EJ (2016). "Zinc acetate lozenges for treating the common cold: an individual patient data meta-analysis". Br J Clin Pharmacol. 82 (5): 1393–1398. doi:10.1111/bcp.13057. PMC 5061795. PMID 27378206.
  5. ^ Hemilä, H; Fitzgerald, JT (2017). "Zinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis". Open Forum Infect Dis. 4 (2) ofx059. doi:10.1093/ofid/ofx059. PMC 5410113. PMID 28480298.
  6. ^ Hemilä H, Chalker E, Tukiainen J (2022). "Quantile Treatment Effect of Zinc Lozenges on Common Cold Duration: A Novel Approach to Analyze the Effect of Treatment on Illness Duration". Frontiers in Pharmacology. 13 817522. doi:10.3389/fphar.2022.817522. PMC 8844493. PMID 35177991.
  7. ^ Hunter J, Arentz S, Goldenberg J, Yang G, Beardsley J, Myers SP, Mertz D, Leeder S (2021). "Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials". BMJ Open. 11 (11) e047474. doi:10.1136/bmjopen-2020-047474. PMC 8578211. PMID 34728441.
  8. ^ Nault D, Machingo TA, Shipper AG, Antiporta DA, Hamel C, Nourouzpour S, Konstantinidis M, Phillips E, Lipski EA, Wieland LS (May 2024). "Zinc for prevention and treatment of the common cold". Cochrane Database Syst Rev (Systematic review). 2024 (5) CD014914. doi:10.1002/14651858.CD014914.pub2. PMC 11078591. PMID 38719213.